Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Archer Materials ( (AU:AXE) ).
In the December quarter of FY26, Archer Materials reported significant technical and strategic progress across its core quantum and biochip programs, including improved quantum state readout for its carbon-based qubit materials, successful synthesis of this material on a one‑inch silicon wafer, and demonstration of room-temperature spin lifetimes that compare favourably with leading quantum platforms. The company broadened its ecosystem by signing a collaboration with Emergence Quantum to explore graphene and carbon-based technologies for next-generation quantum and electronic devices, entered an agreement with CSIRO to develop quantum machine learning models for enhanced financial fraud detection, and, in its Biochip program, achieved clinical-standard accuracy for silicon-based blood potassium testing devices in collaboration with IMEC, a shift that could lower costs, de-risk supply chains and accelerate regulatory and commercial pathways; Archer ended the quarter with $10.3 million in cash (excluding a subsequent $2.1 million R&D tax rebate) and strengthened its board with the appointment of experienced health industry executive Andrew Just as a non-executive director.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
More about Archer Materials
Archer Materials Limited is an Australian quantum technology company developing advanced semiconductor chips for quantum computing, sensing and medical diagnostics, with key programs focused on its 12CQ carbon-based qubit platform and a Biochip for point-of-care blood testing. The company targets next-generation quantum and electronic devices and clinical diagnostics markets, leveraging partnerships with research institutions and industry players to accelerate commercialisation and de-risk technology and supply chains.
Average Trading Volume: 398,897
Technical Sentiment Signal: Buy
Current Market Cap: A$104.5M
Learn more about AXE stock on TipRanks’ Stock Analysis page.